Interim Report Q1 2022

The first quarter in figures

  • Net sales amounted to TSEK 4,260 (2,562).
  • The loss after tax amounted to TSEK 9,736 (8,153).
  • The loss per share amounted to SEK 0.14 (0.15).
  • The cash flow from current operations was negative in the amount of TSEK 10,512 (9,473).
  • The gross margin reached 62.8% (52.7%).
  • Electrode sales volume increased by 33% and reached 9,982 (7,496) units. Repeat sales of electrodes to existing customers increased by 34%.

Important events during the quarter

  • Overall sales increased by 66% (+58%, before currency effects). The sales in the important US market increased within the area of skin cancer by 541% (in local currency by 475%). Sales in Germany increased by 54% (49% in local currency).
  • SciBase Barrier technology part of major immunodermatology project – Next Generation Immunodermatology. The NGID consortium is based in the Netherlands and will run over 6 years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings.
  • A new study from the US supporting the use of Nevisense in diagnosing melanoma was published in „SKIN – The journal of cutaneous medicine“. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.
  • SciBase further strengthened the patent portfolio as patent application: EP Application No. 18729063.0 was granted by EPO in Europe.
  • SciBase announced a change in the Management team and a new head of Quality and Regulatory Affairs

Important events after the end of the     period

  • A new study performed in Germany and published online in the journal Dermato demonstrated the clinical benefits of Nevisense in day-to-day practice

Financial overview   

Apr 1 2021 – 
Jan 1 – Mar 31 Mar 31 2022 Jan 1 – Dec 31
THE GROUP 2022 2021 Rolling-12 2021
Net sales, SEK ths 4 260 2 562 13 425 11 727
Gross margin, % 62,8% 52,7% 58,9% 56,1%
Equity/Asset ratio, % 79,3% 79,6% 79,4% 82,8%
Net indebtness, multiple 0,26 0,26 0,26 0,21
Cash equivalents, SEK ths 54 621 31 403 54 621 65 607
Cashflow from operating activities, SEK ths -10 512 -9 473 -40 540 -39 501
Earnings per share (before and after dilution), SEK -0,14 -0,15 -0,66 -0,67
Shareholder’s equity per share, SEK 0,88 0,70 0,75 1,13
Average number of shares, 000′ 68 475 54 780 66 183 62 739
Number of shares at closing of period, 000′ 68 475 54 780 68 475 68 475
Share price at end of period, SEK 4,70 4,78 4,70 5,52
Number of sold electrodes, pieces 9 982 7 496 32 278 29 792
Average number of employees 18 18 18 17

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 12, 2022.

Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: moc.1660481044esabi1660481044cs@tn1660481044arg.n1660481044omis1660481044

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: es.ce1660481044srota1660481044v@ac1660481044

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.

The post Interim Report Q1 2022 first appeared on Scibase.

SciBase
Muttergesellschaft

Landsvägen 39
172 63 Sundbyberg
Schweden

Besucheradresse
SciBase GmbH
Widenmayerstr. 11
80538 München
Tel.: 089-2007 6939
Tel.: 089 – 2093 1452
ed.es1660481044nesiv1660481044en@of1660481044ni1660481044

Postadresse
SciBase GmbH
Friedrichstr. 154
10117 Berlin
ed.es1660481044nesiv1660481044en@of1660481044ni1660481044